Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I

Background: There have been several studies conducted on the relationship between bipolar mood disorder and attention deficit hyperactivity disorder (ADHD) during the recent years, and in most of them the rate of this association had been estimated as 22-90% and had been reported as noticeable. The goal of this study is to determine the prevalence of ADHD in patients with Bipolar mood disorder type I (BID).Materials and Methods: In this Cross-sectional study, 152 patients with BID that were referred to psychiatric clinic of Tehran psychiatric Institute for a better observation and treatment were included. Two questionnaires, Wender’s for childhood ADHD and Conner’s’ for adulthood ADHD were filled by the patients.Results: 102 patients (67%) were males and 50 were females. The average age of patients at the time of our study (with the minimum of 17 and maximum of 76) was 33.5±10.9. The prevalence of ADHD in our patients was 11.8%. 46 people (30.9%) had a history of childhood ADHD. 21 persons had adult ADHD from whom only 3 ones mentioned a history of childhood ADHD (which means 18 people of our adulthood ADHD had no history of childhood ADHD).Conclusion: Since some treatments lead to improvement of ADHD and worsening of BID, investigations on their correlations and their alternative treatments seemed to be necessary. This study showed a significant correlation between ADHD and BID, which was similar to the results of other studies in this field.

Download Full-text

Attention deficit hyperactivity disorder associated with lissencephaly type I

Sakarya Medical Journal ◽

10.5505/sakaryamj.2012.94830 ◽

2012 ◽

Vol 2 (1) ◽

pp. 42-45

Author(s):

Tulin Fidan ◽

Dilcan Kotan ◽

Ismet Kirpinar

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Attention Deficit ◽

Type I ◽

Hyperactivity Disorder

Download Full-text

Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior Disorders

10.1093/med:psych/9780199342211.003.0004 ◽

2015 ◽

Author(s):

Erica Kass ◽

Jonathan E. Posner ◽

Laurence L. Greenhill

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Randomized Controlled Trials ◽

Disruptive Behavior ◽

Attention Deficit ◽

Behavior Disorders ◽

Disruptive Behavior Disorders ◽

Controlled Trials ◽

Type I ◽

Hyperactivity Disorder ◽

Randomized Controlled

More than 225 placebo-controlled type 1 investigations demonstrate that psychostimulants are highly effective in reducing core symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adults. In contrast, there are limited type I studies demonstrating that psychopharmacological management with U.S. Food & Drug Administration-approved agents for ADHD (stimulants and nonstimulants), atypical antipsychotics, and mood stabilizers decrease the defiant and aggressive behavior characteristic of disruptive behavior disorders. Stimulant treatment evidence has been supplemented by two large multisite randomized controlled trials. Randomized controlled trials from the past 15 years continue to report several key adverse events associated with stimulants but have not supported rarer and more serious problems. Although psychostimulants have been shown to retain their efficacy for as long as 14 months, their long-term academic and social benefits are not as robust. Nonstimulant agents for which there is more limited evidence of efficacy include atomoxetine, alpha-agonists, modafinil, and bupropion.

Download Full-text

Chiari Malformation and Attention Deficit Hyperactivity Disorder

Case Reports in Medicine ◽

10.1155/2020/2694956 ◽

2020 ◽

Vol 2020 ◽

pp. 1-3

Author(s):

Anaïs DuBow ◽

Aurélie Mourot ◽

Smadar Valérie Tourjman

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Ct Scan ◽

Attention Deficit ◽

Chiari Malformation ◽

Foramen Magnum ◽

Type I ◽

Chiari Malformation Type I ◽

Hyperactivity Disorder ◽

Chiari Malformations

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity. Chiari malformations (CM), first described approximately a hundred years ago, refer to a spectrum of hindbrain malformations characterized by cerebellar herniation through the foramen magnum. We present the case of a 28-year-old woman with ADHD and concurrent Chiari malformation type I (CM-I) that was diagnosed by CT scan. There is growing evidence supporting the role of the cerebellum and its associated structures in the pathophysiology of ADHD. Thus, a cerebellar malformation such as CM may impact neurological circuitry in a manner favoring the development of a neuropsychiatric disorder such as ADHD. Our case highlights the need for further studies pertaining to the role of the cerebellum in the pathophysiology of ADHD and the importance of considering the presence of CM when evaluating a patient with ADHD.

Download Full-text